Mangalam drugs & organics Limited has successfully concluded its board meeting on March 26, 2026, officially approving significant changes in its Company Secretary position. The board meeting, held at the company's registered office in Mumbai, addressed the planned transition in key managerial personnel as previously announced.

Board Meeting Outcome

The board meeting commenced at 12:00 PM and concluded at 12:40 PM on Thursday, March 26, 2026. The meeting was conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring compliance with regulatory requirements for material disclosures.

Personnel Changes Approved

The board formally approved two critical agenda items related to the Company Secretary transition:

Ms. Anuradha Pandey's resignation from the position of Company Secretary & Compliance Officer was officially accepted by the board. Her resignation letter, dated January 2, 2026, cited her decision to pursue opportunities outside the company. Her last day of service will be March 29, 2026.

New Company Secretary Profile

The board approved the appointment of Ms. Shweta Patel as the new Company Secretary & Compliance Officer, effective April 1, 2026. Ms. Patel brings relevant qualifications and experience to the role:

Ms. Patel is an Associate Member of the Institute of Company Secretaries of India and has three years of experience handling corporate compliances with statutory and regulatory requirements for listed companies, along with public and private company groups.

Regulatory Compliance

The company has communicated the board meeting outcomes to both BSE Limited and National Stock Exchange of India Limited as required under listing regulations. The notification was signed by Chairman & Managing Director Govardhan M. Dhoot, ensuring proper disclosure of material changes in key managerial positions.

Mangalam drugs & organics Limited has disclosed its latest bank loan default figures, with total overdue amounts remaining unchanged at ₹1,585.29 lakh across two major banking institutions. The pharmaceutical company made this subsequent disclosure on March 17, 2026, under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, showing no change from its previous February notification.

Current Default Status and March Update

The company's loan defaults continue to involve cash credit facilities with two prominent banks, with the latest disclosure showing identical overdue amounts as of March 15, 2026:

The figures remain identical to those reported in February 2026, indicating no progress in reducing the outstanding obligations despite continued efforts by the management. The defaults have now persisted for approximately five months since their inception in October 2025.

Regulatory Compliance and Disclosure Timeline

The March 17, 2026 disclosure was made in compliance with SEBI regulations that require listed entities to report defaults on loan obligations when outstanding balances remain continuously in excess of sanctioned limits or drawing power for more than 30 days. The company filed its subsequent disclosure with both BSE Limited and National Stock Exchange of India Limited, providing updated details of the defaulted accounts.

This represents the latest in a series of monthly disclosures, following previous notifications in February 2026 and January 2026, demonstrating the persistent nature of the financial challenges and the company's commitment to regulatory transparency.

Management Response and Ongoing Efforts

Mangalam Drugs and Organics Limited has acknowledged the continued defaults and reiterated its commitment to addressing the situation. The company stated it is making arrangements to pay the overdue amounts as soon as possible, maintaining its position on resolving the financial obligations despite no apparent progress in the past month.

The disclosure was signed by Managing Director Govardhan M. Dhoot, with Chief Financial Officer Jeevan Dalvi also involved in the internal communication process. The company has assured stakeholders that efforts remain underway to clear the outstanding dues with both banking institutions, though the unchanged figures suggest ongoing challenges in debt resolution.